20.500.12556/DiRROS-30275 Adjuvant nivolumab in resected oesophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy Slovenian real-world data Adjuvant nivolumab has become the new standard of care for patients with oesophageal and gastroesophageal junction cancer (OEC/GEJC) following neoadjuvant chemoradiotherapy (neoCRT) and surgical resection. In Slovenia, this treatment has been in use since January 2022. Here, we report the first Slovenian real-world experience with adjuvant nivolumab. Patients and methods. We conducted a retrospective, observational cohort study of patients with OEC/GEJC who received adjuvant nivolumab after neoCRT and radical resection between January 2022 and December 2023. Data on patient characteristics, treatment completion, disease progression, and immune-related adverse events (irAEs) were collected from medical records and analysed via descriptive statistics. Results. A total of 17 patients were included. The median follow-up was 34.6 months (range 11.2–55.7). The cohort included 14 (82%) males, with a mean age of 59 years. The Eastern Cooperative Oncology Group (ECOG) performance status was 0 for 15 (88%) patients and 1 for 2 (12%) patients. The tumor location was the esophagus in 9 (53%) patients and the gastroesophageal junction in 8 (47%) patients. At diagnosis, 13 (76%) patients were stage III (8th TNM classification). Histology revealed adenocarcinoma (AC) in 12 (71%) patients and squamous cell carcinoma (SCC) in 5 (29%) patients. Only 6 (35%) patients completed one year of adjuvant nivolumab. Treatment was discontinued in 5 (29%) patients due to disease progression and in 6 (35%) patients due to irAEs. Overall, 11 (65%) patients experienced irAEs of any grade. Grade 3 or 4 irAEs occurred in 4 (24%) patients: myocarditis G4 in 1 (6%) patient and colitis G3 in 3 (18%) patients. No irAE-related deaths were reported. The median disease-free survival (DFS) was 21.4 months (95% confidence interval [CI], 14.6–28.9). Conclusions. Real-world data from Slovenia indicate that 65% of patients discontinued adjuvant nivolumab prematurely due to disease progression or irAEs. These findings highlight the need for careful patient selection and monitoring when using adjuvant immunotherapy in this population. oesophageal cancer gastroesophageal junction cancer adjuvant immunotherapy nivolumab rak požiralnika rak gastroezofagealnega prehoda adjuvantna imunoterapija nivolumab true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik Neznano 2026-06-18 10:35:52 2026-06-18 10:35:53 2026-06-19 03:51:58 0000-00-00 00:00:00 2026 0 0 str. [1-6] no. Vol. 60 2026 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2026-01-01 616.3 1318-2099 10.2478/raon-2026-0020 275560707 RAZ_Hribernik_Nezka_2026.pdf RAZ_Hribernik_Nezka_2026.pdf 1 0C57D2E134B4348EAE525F543DC8162F a1ce1996f92817364977fd6fa1c7b1cdfba09ee2d5449f693fa195942a154d6b d8c27b35-6ae8-11f1-be3d-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=45895 Društvo radiologije in onkologije Onkološki inštitut Ljubljana 0 0 0